



VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.
H.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Quthbullapur, Hyderabad,
Medchal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

14th November, 2018

To
The General Manager,
Department of Corporate Services,
The BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, M Samachar Marg, Fort
Mumbai, Maharashtra 400001

Dear Sirs / Madam

Sub: Outcome of the Board Meeting held today & Submission of Un-Audited Financial Results for the 2nd quarter and half year ended 30th September, 2018.

Ref: BSE Scrip Code: VENMAX/531015

In compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith the un-audited Financial Results of Venmax Drugs And Pharmaceuticals Ltd for the 2nd and half year ended September 30, 2018, as approved by the Board of Director at their meeting held today i.e. 14th November, 2018 at 4.00 P M and concluded at 4.45 PM.

You are requested to take the same on record and acknowledge.

Thanking you.

Yours faithfully

For Venmax Drugs And Pharmaceuticals Ltd

Raj Kumar Rai
Managing Director
DIN: 00009207



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.
H.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Quthbullapur, Hyderabad,
Medchal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

VENMAX DRUGS AND PHARMACEUTICALS LIMITED
(CIN: L24230TG1988PLC009102)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September 2018

S.NO	Particulars	Quarter ended			Half-Year ended		Year ended 31.03.2018 (Audited)
		30.09.2018 (UnAudited)	30.06.2018 (UnAudited)	30.09.2017 (UnAudited)	30.09.2018 (UnAudited)	30.09.2017 (UnAudited)	
1	2	3	4	5	6	7	8
1	Revenue						
	(a) Revenue from operations	1.12	-	-	1.12	-	-
	(b) Other Income	0.21	-	-	0.21	-	-
	Total Revenue (a+b)	1.33	-	-	1.33	-	-
2	Expenses						
	Cost of materials consumed	2.30	-	-	2.30	-	-
	Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee Benefit Expense	1.90	1.32	1.40	3.22	2.71	5.37
	Financial costs	-	-	-	-	-	-
	Depreciation and amortization expense	0.04	-	-	0.04	-	-
	Other Expenses	5.69	0.53	2.24	6.22	2.61	18.84
	Total Expenses (a+b+c+d+e+f)	9.93	1.85	3.64	11.78	5.32	24.22
3	Profit before exceptional items & tax (1-2)	(8.60)	(1.85)	(3.64)	(10.45)	(5.32)	(24.22)
4	Exceptional items	-	-	-	-	-	-
5	Profit before tax (3-4)	(8.60)	(1.85)	(3.64)	(10.45)	(5.32)	(24.22)
6	Tax Expense:						
	(a) Current tax	-	-	-	-	-	-
	(b) Deferred tax	0.32	-	-	0.32	-	-
	Total Tax Expense (a+b)	0.32	-	-	0.32	-	-
7	Profit after tax (5-6)	(8.93)	(1.85)	(3.64)	(10.78)	(5.32)	(24.22)
8	Other Comprehensive income						
	(a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
	(b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
	Total other comprehensive income (net of tax) (a+b)	-	-	-	-	-	-
11	Total comprehensive income (9+10)	(8.93)	(1.85)	(3.64)	(10.78)	(5.32)	(24.22)
12	Paid up equity share capital (Face Value of share Rs.10/- each)	523.89	523.89	523.89	523.89	523.89	523.89
13	Other equity						(735.19)
14	Earnings per share (Face value of rs.10/- each):	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic	(0.17)	(0.04)	(0.07)	(0.21)	(0.10)	(0.46)
	(a) Diluted	(0.17)	(0.04)	(0.07)	(0.21)	(0.10)	(0.46)

Notes

- The above results of Unaudited financials have been reviewed by Audit Committee and approved by Board of Directors at the board meeting held on 14-11-2018.
- The Board of Directors has not recommended any dividend.
- The above statement have been prepared to the extent applicable, in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company w.e.f.01.04.2017. The financial results of the previous periods duly complied with Ind AS have not been subjected to review or audit, however, the Management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs.
- Previous Quarters/Year's figures have been regrouped/rearranged wherever necessary to confirm to the classification for the current quarter / year.
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The Company is engaged in activities of trading of bulk drugs, intermediates and chain of retail pharmacy outlets.

For Venmax Drugs And Pharmaceuticals Limited

M.A.N.A. Director
6/2/18



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.
H.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Quthbullapur, Hyderabad,
Medchal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

Venmax Drugs and Pharmaceuticals Limited
Standalone Balance Sheet

CIN: L24230TG1988PLC009102

H.No.1-140,Rajeswari warehouse,Opposite to Sri convention,kompally,Quthbullapur,Hyderabad,500014.

(All amounts in Indian Rupees, except share data and where otherwise stated)

	Note	As at 30 September 2018	As at 31 March 2018
Assets			
Non-current assets			
(a) Property, Plant and Equipment	4	30,070	-
(b) Other Intangible assets	4	289,985	-
(c) Financial assets			
Investments	5	-	-
Loans	6	-	-
(d) Deferred tax assets, net	7	-	-
		<u>320,055</u>	<u>-</u>
Current assets			
Inventories		403,816	-
Financial assets			
Trade receivables	8	-	-
Cash and cash equivalents	9	141,269	37,425
Current tax assets		374,570	374,570
Other current assets	10	425,097	308,148
		<u>1,344,752</u>	<u>720,143</u>
Total assets		<u>1,664,807</u>	<u>720,143</u>
Equity and Liabilities			
Equity			
Equity share capital	11	52,389,300	52,389,300
Other equity	12	(74,596,073)	(73,518,516)
Total equity		<u>(22,206,773)</u>	<u>(21,129,216)</u>
LIABILITIES			
Non-current liabilities			
Deferred tax liabilities (Net)	28	32,485	-
Total Non-current liabilities		<u>32,485</u>	<u>-</u>
Current liabilities			
Financial Liabilities			
Borrowings	13	20,910,224	20,378,150
Trade payables	14	1,618,560	592,039
Other financial liabilities	15	1,231,298	800,158
Other current liabilities	16	79,012	79,012
Total Current liabilities		<u>23,839,094</u>	<u>21,849,359</u>
Total equity and liabilities		<u>1,664,807</u>	<u>720,143</u>
Summary of significant accounting policies	3		

The accompanying notes are an integral part of the standalone financial statements.

for and on behalf of the Board of Directors of
Venmax Drugs and Pharmaceuticals Limited


Raj Kumar Rai
Managing Director
DIN: 00009207

G L N PRASAD & CO LLP

CHARTERED ACCOUNTANTS

Limited Review Report

To
The Board of Directors
VENMAX DRUGS AND PHARMACUETICALS LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of Venmax Drugs And Pharmaceuticals Limited (the 'Company') for the quarter ended 30th September, 2018 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS) 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 13.11.2018

For G L N Prasad & Co LLP
Chartered Accountants

FRN: 015176S/S200067


Ch. Ramakrishna

Partner

Membership No.: 226417

